A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients with Advanced Solid Tumors

Protocol No
SANOFI-TED13751
Principal Investigator
Jonathan Thompson
Phase
I
Summary
SAR408701 consists of a drug component called DM4 that is to kill tumor cells. This drug is linked to an antibody that recognizes a protein called CEACAM5 that is expressed at the surface of some types of cancer (cancers of the colon and rectum, lung, stomach, pancreas, uterus, ovaries, bladder and gallbladder and its ducts, to name the more important). The antibody component of SAR408701 binds to the CEACAM5 antigen expressed at the surface of the tumor cell. Then SAR408701 enters the tumor cells and the drug DM4 kills the cell. In summary, SAR408701 is a system to deliver an anticancer drug specifically to the tumor cells that express the CEACAM5. The CEACAM5 antigen is a molecule which is normally produced during fetal development; its production stops before birth. In adults, CEACAM5 expression at the cell membrane of normal cells is limited to few organs or tissues, and the expression is less important.
Description
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: